NCT04504071View on ClinicalTrials.gov

Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 8, 2020

Primary Completion Date

December 15, 2022

Study Completion Date

December 1, 2027

Conditions
Non-small Cell Lung Cancer MetastaticEGF-R Positive Non-Small Cell Lung Cancer
Interventions
DRUG

Dacomitinib

Patients will receive continuous oral therapy with the study drugs (dacomitinib 45 mg) until disease progression or unacceptable toxicity.

Trial Locations (1)

200030

Shanghai Chest hospital, Shanghai

All Listed Sponsors
lead

Shanghai Chest Hospital

OTHER